← Back to all trials
Completed
NCT05659095
Autologous Hair Follicle Derived Mesenchymal Stem Cell Suspension to Treat AGA
Conditions: Hair Transplantation
Sex: All
Ages: 25 Years – 45 Years
Healthy volunteers: 1
Phase: NA
Enrollment: 50
Sponsor: Nanfang Hospital of Southern Medical University
Location: China
Summary
Androgenic alopecia (AGA) is characterized by progressive hair follicle miniaturization, and novel treatments are needed to intervene in the miniaturization process.
The investigators aimed to evaluate the efficacy, safety, effectiveness, and effective population of autologous hair follicle mesenchymal stem cell therapy for the treatment of advanced AGA in Chinese people.50 participants ranging from 25 to 45 years old, with an average age of 32 ± 1.24 years were included.
None of them had ever used minoxidil, finasteride, or other drugs to promote hair growth.
Healthy hair follicles were extracted from the occipital area and treated to obtain hair follicle mesenchymal stem cells suspensions.
The recipient sites were divided into two groups.
Nine points were injected in a 1 cm2 area, and 100 μl of solution containing either 1 × 105 cells or normal saline was injected at each point.
The follow-up duration was 9 months.
Observers were blinded to patient groupings and measurements.
Eligibility Criteria
Inclusion Criteria:Clinical diagnosis of Androgenic alopeciaAGA classification include：The Norwood grade for male hair loss was II-V, and the Ludwig grade for female hair loss was I-IIIExclusion Criteria:(1) Using medications or supplements, including finasteride, dutasteride, ketoconazole, minoxidil or any other hormonal products, that can affect hair growth;(2) Patients with severe systemic diseases, immune diseases, endocrine diseases and nervous system diseases;(3) Patients with head skin infection, allergic disease and malignant tumor
Source: ClinicalTrials.gov (NCT05659095). StuddyBuddy aggregates publicly available trial information.
